Cudurka Rheumatoid waa xaalad naadir ah oo aad u daran oo ku dhaca rheumatoid arthritis taas oo suurogal u noqon karta nolol-halis. Xanuunku wuxuu ku faafaa xididdada dhiigga yar ama mid dhexdhexaad ah ee jidhka. Badanaa, halbowlayaasha ayaa ku lug leh, laakiin xididada ayaa sidoo kale noqon kara sidoo kale. Maraakiib dhiig ah oo aad u badan ayaa ku lug leh.
Darbiyada xididdada dhiigga ee bararsan ayaa sii yaraada oo marka lumen ee marinka dhiigga uu saameeyo, waxaa laga yaabaa inay noqoto mid xiran.
Dhiiga dhiigga ee jirka waa laga yaabaa in markaa la jabiyo, haddii aan la diideyn. Cudurka Rheumatoid-ka wuxuu ku lug yeelan karaa xubnaha jirka, oo ay ku jiraan maqaarka, indhaha, dareemayaasha, wadnaha, sambabada, maskaxda, maskaxda, kelyaha, ama mareenka caloosha. Laakiin, waxaa jira war wanaagsan. Bukaannada yar ee rheumatoid arthritis-ku waxay ku dhacaan xummad rheumatoid ah, oo laga yaabo inay keento daawooyin wax ku ool ah oo waxtar leh oo la kobciyay iyo suuq-gareeyey tobankii sano ee la soo dhaafay (sida, daawooyinka bayoloji ).
Is-beddelka iyo Khatarta Rexumatoid Vasculitis
Inkasta oo uu cudurku ku yar yahay vasulitis-ka, haddana waxaa lagu qiyaasay in ka yar hal illaa 5% dadka bukaanka qaba cudurka rheumatoid arthritis-ka uu ku dhaco xanuunka rheumatoid. Si kastaba ha ahaatee, daraasadaha qalliinka ayaa soo sheegay 15-31%. Saamaynta iyo dhimashada heerka dhimashada rheumatoid-ka ayaa muhiim u ah heerka dhimashada 5 sanno ee 30-50% iyada oo xitaa heerarka cudurrada ee xitaa ay ku xiran yihiin dhibaatooyinka cudurka ama daaweynta sunta.
Waxyaabaha soo socda ayaa kordhiya khatarta ah in uu ku dhaco bogsasho xajiin ah:
- Ku fiicnaanshaha saameynta rheumatoid
- Ku fiicnaanshaha ka hortagga CCP
- Labo (9kii ninba midka qaba rheumatoid arthritis-ku wuxuu horumariyaa xajmiga rheumatoid)
- Sigaar cabid
- Jiritaanka calaamadaha cudurka rheumatoid
- Ciyaalka weyn ee bilawga ama muddada dheer ee rheumatoid arthritis-ka (10 sano ka weyn)
Astaamaha iyo Caddaynta Caabuqa Cudurka Rheumatoid
Xubin kasta oo jidhka ah ayaa saameeya xajmiga rheumatoidka. Maqaarka iyo dareeraha dareenka ayaa inta badan ku lug leh. In kasta oo ku lug lahaanshaha qaybta xubinta taranka, haddana waxay la xiriirtaa cudurrada iyo dhimashada weyn.
Ka-qaybgalka maqaarka waxaa ka mid noqon kara purpura, nodules, boogaha, iyo necrosis ee tirooyinka, gaar ahaan faraha. Liveso reticularis waa natiijo caadi ah. Ka qayb qaadashada maqaarku waxay ku baaqeysaa in baaritaan dheeraad ah lagu sameeyo ka qaybgalka xubnaha kale. Cudurka xasaasiyadda , pleuriitis , ama pericarditis ayaa ah tusaalooyin ah waxa laga yaabo inuu horumar sameeyo. Haddii maqaarku ku lug yeesho iyada oo aan jirin nidaam kale oo nidaamsan, prognosis waa ka fiican tahay.
Nidaamka walxaha dareemayaasha ah, neuropathy xannibaadyada ayaa laga yaabaa inay soo baxaan, sida polyneuropathy dareen dareen-celin ah, mishiinka indhaha ama isku-dhafka neuropathy, ama mononeuritis multiplex. Marka uu bogsashadu waxyeelo dareemayaasha. waxaa jiri kara kabuubyo, xatooyo, lumitaan dareemid, daciifnimo, iyo luminta shaqeynta gacmaha ama lugaha. Calaamadaha guud ee badanaa way dhici karaan, sida qandho, miisaan lumis, cunto xumo, lumid tamar.
Baadhitaanka cudurka Rheumatoid Vasculitis
Inkasta oo astaamaha calaamadaha ay sababi karaan dhakhtarka inuu ka shakiyo bogga xajmiga rheumatoidka iyo tijaabooyinka shaybaarka ayaa bixin kara caddaynta taageerada ee loo yaqaan 'diagnosisable diagnosis', waxaa loo baahan yahay cad ka-qaadis cad.
Maqaarka la soo galiyay waxaa laga yaabaa in la xoqo, iyo sidoo kale muruq ama dareen-wadareed gudniinka, ama hay'ad saameysa.
Inkastoo baaritaanka dhiigga loogu talagalay astaamaha rheumatoid-ka iyo anti-CCP ay caadi ahaan sare u kaceen xajmiga bakteeriyada rheumatoid, natiijooyinka maaha kuwo gaar ah. Labada nooc ee difaaca jirka waxay sidoo kale ku badan yihiin rheumatoid arthritis oo aan lahayn vasculitis. Anti-neutrophil cytoplasmic antibodies (ANCA) iyo la-xiriirka antiel-methoperoxidase iyo antibiyootikada-anti-protein-ka ayaa caadi ahaan xumaynaya xiidanka rheumatoid.
Daaweynta Cudurka Rheumatoid Vasculitis
Daaweynta bogsashooyinka rheumatoid-ka waxaa inta badan go'aaminaya hay'adaha ku lug leh.
Sidoo kale, rheumatoid arthritis waa in si macquul ah loola dhaqmaa iyadoo la isticmaalayo DMARD ama daroogooyinka bayoolajiga, sida TNF-blockers . Xakamaynta bararka labada lugood iyo xididdada dhiigga waa muhiim.
Qeybta koowaad ee daaweynta xanuunka 'rhomatoid vasculitis' waxaa ka mid ah isticmaalka corticosteroids (badanaa prednisone ). Prednisone waxaa lagu dari karaa daawada methotrexate ama azathioprine. Calaamadaha ugu horumarsan iyo ka qaybgalka xubnaha jirka, dadaal aad u daran oo loogu talagalay immunosuppression waxay ku jiri karaan cyclophosphamide iyada oo ay weheliso qiyaaso badan oo prednisone ah. Rituxan (rituximab) ayaa ka soo baxaaya sida daaweynta safka hore ee xajmiga xanuunka rheumatoid. Sida laga soo xigtay warbixin ku saabsan Arthritis Care iyo Research (2012), falanqaynta xogta laga helay diiwaanka "Autoimmunity" iyo "Rituximab" ayaa muujisay in ka-fadhiisinta 12-kii 17-kii bukaan-socodka rheumatoid-ka loo yaqaan rituximab. Bukaannada ayaa sidoo kale awood u yeeshay in ay yareeyaan qiyaasta qiyaasta daawada loo yaqaan 'prednisone'.
Ilaha:
Cudurka Rheumatoid Vasculitis. Johns Hopkins Xarunta Vasculitis Center.
http://www.hopkinsvasculitis.org/types-vasculitis/rheumatoid-vasculitis/
Cudurka Rheumatoid Vasculitis. Cleveland Clinic.
http://my.clevelandclinic.org/services/orthopaedics-rheumatology/diseases-conditions/hic-rheumatoid-vaskelitis
Cudurka Rheumatoid Vasculitis. Vaschitis Foundation. Sebtembar 2012.
http://www.vasculitisfoundation.org/education/forms/rheumatoid-vasculitis/
Cudurka Rheumatoid Vaskitit: Maqnaanshaha Xanuunka ama Targetida Daaweynta Cusub? Bartels iyo Bridges. Warbixinnada Rootology ee hadda. Diisambar 2010.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950222/
Daaweynta Rituximab ee loogu talagalay dheecaanka nidaamsan ee la xiriira rheumatoid arthritis: Natiijooyinka ka yimaada Diiwaangelinta Macaamiishu iyo Rituximab. Puechal X et al. Arthritis Care iyo Research. Maarso 2012.
http://www.ncbi.nlm.nih.gov/pubmed/22076726